Literature DB >> 12498108

Immunity and schizophrenia: autoimmunity, cytokines, and immune responses.

Fiona Gaughran1.   

Abstract

As is evident from the present account, there is no single or persuasive argument that signals emanating from the immune system are directly involved in the etiology of schizophrenia. We do not even know if we are dealing with a single disorder with a single causality; almost certainly we are not. The precise etiology of schizophrenia, as with so many neurological disorders, remains obscure. However, there is abundant evidence in schizophrenia of mutual dysregulation of neuronal function and immune system activity. Although this evidence is not always consistent, a pattern emerges suggesting aspects of immune activity being involved in the pathology of neuronal development that characterizes schizophrenia. Exposure to infective agents, HLA associations, autoimmune associations, disturbances in lymphocyte populations, and cytokine imbalances with a skew toward Th2 activity are supportive of this view. That the evidence is not always consistent is a testament to the complexity and heterogeneity of the disorder, to confounding by antipsychotics that themselves are immunomodulatory, and to the multifaceted nature, with all its checks and balances, of the immune system itself.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498108     DOI: 10.1016/s0074-7742(02)52013-4

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  15 in total

Review 1.  The complement system in schizophrenia.

Authors:  Karine R Mayilyan; Daniel R Weinberger; Robert B Sim
Journal:  Drug News Perspect       Date:  2008-05

2.  Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication.

Authors:  Gwyneth Zai; Daniel J Müller; Jan Volavka; Pal Czobor; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy
Journal:  Psychopharmacology (Berl)       Date:  2006-08-24       Impact factor: 4.530

Review 3.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 5.  Omega-3 fatty acids in the treatment of psychiatric disorders.

Authors:  Malcolm Peet; Caroline Stokes
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Behavioral heterogeneity in an animal model of neuropsychiatric lupus.

Authors:  Boris Sakic; Steven E Hanna; Jason M Millward
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

Review 7.  Neuroimmune pharmacology of neurodegenerative and mental diseases.

Authors:  Feng-Shiun Shie; Yun-Hsiang Chen; Chia-Hsiang Chen; Ing-Kang Ho
Journal:  J Neuroimmune Pharmacol       Date:  2010-09-07       Impact factor: 4.147

8.  Effect of chronic treatment with perazine on lipopolysaccharide-induced interleukin-1 beta levels in the rat brain.

Authors:  Ewa Obuchowicz; Agnieszka Marcinowska; Lukasz Drzyzga; Jacek Wójcikowski; Władysława A Daniel; Zbigniew S Herman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-01       Impact factor: 3.000

9.  Association study of CSF2RB with schizophrenia in Irish family and case - control samples.

Authors:  Q Chen; X Wang; F A O'Neill; D Walsh; A Fanous; K S Kendler; X Chen
Journal:  Mol Psychiatry       Date:  2007-07-31       Impact factor: 15.992

10.  Perinatal complications and schizophrenia: involvement of the immune system.

Authors:  Trisha A Jenkins
Journal:  Front Neurosci       Date:  2013-06-25       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.